1. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors
- Author
-
Pravien Abeywickrema, Shawn J. Stachel, Tamara D. Cabalu, Anthony T. Ginetti, Yili Chen, Daniel V. Paone, Michael P. Dwyer, Jonathan E. Wilson, Deping Wang, Alejandro Crespo, Jun Lu, Christopher Joseph Sinz, Gregori J. Morriello, and Shimin Xu
- Subjects
Models, Molecular ,Steric effects ,Phosphodiesterase Inhibitors ,education ,Clinical Biochemistry ,Binding pocket ,Pharmaceutical Science ,Pyrimidinones ,Crystallography, X-Ray ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,chemistry.chemical_compound ,Drug Discovery ,Humans ,Molecular Biology ,chemistry.chemical_classification ,Dose-Response Relationship, Drug ,Molecular Structure ,010405 organic chemistry ,Chemistry ,fungi ,Organic Chemistry ,Cyclic Nucleotide Phosphodiesterases, Type 2 ,Combinatorial chemistry ,0104 chemical sciences ,Amino acid ,010404 medicinal & biomolecular chemistry ,Pyrazoles ,Molecular Medicine ,Selectivity ,Lead compound - Abstract
A focused SAR study was conducted on a series of N1-substituted pyrazolopyrimidinone PDE2 inhibitors to reveal compounds with excellent potency and selectivity. The series was derived from previously identified internal leads and designed to enhance steric interactions with key amino acids in the PDE2 binding pocket. Compound 26 was identified as a lead compound with excellent PDE2 selectivity and good physicochemical properties.
- Published
- 2021